Table 2.
Baseline clinical characteristics of COVID-19 patients
| Parameter | PE− | PE+ | P |
|---|---|---|---|
| Gender, n (%) | 0.33 | ||
| F | 13 (27.7) | 9 (19.1) | |
| M | 34 (72.3) | 38 (80.9) | |
| Obesity, n (%) | 0.49 | ||
| No | 35 (74.5) | 32 (68.1) | |
| Yes | 12 (25.5) | 15 (31.9) | |
| Smoking, n (%) | 0.06 | ||
| Former | 6 (12.8) | 15 (31.9) | |
| No | 27 (57.4) | 24 (51.1) | |
| Yes | 14 (29.8) | 8 (17.0) | |
| T2D, n (%) | 0.18 | ||
| No | 36 (76.6) | 30 (63.8) | |
| Yes | 11 (23.4) | 17 (36.2) | |
| Hypertension, n (%) | 0.67 | ||
| No | 17 (36.2) | 19 (40.4) | |
| Yes | 30 (63.8) | 28 (59.6) | |
| CHD, n (%) | 0.58 | ||
| No | 38 (80.9) | 40 (85.1) | |
| Yes | 9 (19.1) | 7 (14.9) | |
| COPD, n (%) | 1.00 | ||
| No | 44 (93.6) | 44 (93.6) | |
| Yes | 3 (6.4) | 3 (6.4) | |
| ACEi, n (%) | 0.53 | ||
| No | 27 (57.4) | 30 (63.8) | |
| Yes | 20 (42.6) | 17 (36.2) | |
| SARTANS, n (%) | 0.38 | ||
| No | 33 (70.2) | 29 (61.7) | |
| Yes | 14 (29.8) | 18 (38.3) |
ACEi angiotensin-converting enzyme inhibitors, CHD coronary heart disease, COPD chronic obstructive pulmonary disease, F female, M male, T2D type 2 diabetes